Copenhagen, a hub of big players in the space of metabolic diseases, has now witnessed another addition- a biotech startup called the Antag Therapeutics.
Most obesity drugs or medications on the market enable a weight loss of about 10%, but are all associated with significant side effects.
The startup aims at developing treatment strategies for growing number of patients with obesity. It is presently focusing on formulating a peptide-based therapeutic- antagonist of the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor, which is known to play a major role in glucose homeostasis and lipid metabolism with known effects on obesity and insulin resistance; with the help of which the company intends to provide for the treatment of dietary related metabolic diseases. It is spinout of the University of Copenhagen, based on the research of Mette M. Rosenkilde and Jens J. Holst.
The leading Nordic VC Novo Seeds seems to be convinced of the idea and hence has been backing the research team since 2014 and just handed the biotech a €2.7M Seed Investment.
